| The NAD(P)H oxidase inhibitor apocynin improves endothelial NO/superoxide balance and lowers effectively blood pressure in spontaneously hypertensive rats: comparison to calcium channel blockade. | |
| | |
MedLine Citation:
|
PMID: 17653964 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The vascular NAD(P)H oxidase contributes to endothelial dysfunction and high blood pressure in the spontaneously hypertensive rat by enhancing superoxide production. We investigated the effects of apocynin, a NAD(P)H oxidase inhibitor, on blood pressure and vascular radical and nitric oxide formation in SHR and compared its effects to the calcium channel blocker nifedipine. Apocynin (over four weeks) lowered systolic blood pressure significantly and as effectively as nifedipine. Both apocynin and nifedipine significantly reduced superoxide production. In parallel, vascular nitric oxide production and ecNOS activity was significantly increased by apocynin treatment. Therefore, apocynin may be an effective antihypertensive drug in essential hypertension. |
| | |
Authors:
|
Anselm T Bäumer; Christian A Krüger; Juliane Falkenberg; Henrik Ten Freyhaus; Renate Rösen; Klaus Fink; Stephan Rosenkranz |
Related Documents
:
|
15723574 - Use of nifedipine in the treatment of hypertension. 2580184 - Effect of chronic nifedipine in patients inadequately controlled by a converting enzyme... 3471914 - Calcium channel blockade with nifedipine reduces the systemic and the pulmonary vascula... 8482884 - The effect of nifedipine [correction of nifidipine] and cimetidine on the haemodynamics... 15723574 - Use of nifedipine in the treatment of hypertension. 451554 - Racial differences in blood pressure control. |
Publication Detail:
|
Type: Comparative Study; In Vitro; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Clinical and experimental hypertension (New York, N.Y. : 1993) Volume: 29 ISSN: 1064-1963 ISO Abbreviation: Clin. Exp. Hypertens. Publication Date: 2007 Jul |
Date Detail:
|
Created Date: 2007-07-26 Completed Date: 2007-09-14 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9305929 Medline TA: Clin Exp Hypertens Country: United States |
Other Details:
|
Languages: eng Pagination: 287-99 Citation Subset: IM |
Affiliation:
|
Klinik III für Innere Medizin, Universität zu Köln, Köln, Germany. Anselm.Baeumer@uk-koeln.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acetophenones
/
pharmacology* Animals Blood Pressure / drug effects Calcium Channel Blockers / pharmacology Endothelium, Vascular / drug effects, metabolism Enzyme Inhibitors / pharmacology* Hypertension / drug therapy*, physiopathology* Male NADPH Oxidase / antagonists & inhibitors* Nifedipine / pharmacology Nitric Oxide / metabolism Nitric Oxide Synthase Type III / metabolism Rats Rats, Inbred SHR Reactive Oxygen Species / metabolism Superoxide Dismutase / metabolism Vasoconstriction / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Acetophenones; 0/Calcium Channel Blockers; 0/Enzyme Inhibitors; 0/Reactive Oxygen Species; 10102-43-9/Nitric Oxide; 21829-25-4/Nifedipine; 498-02-2/acetovanillone; EC 1.14.13.39/Nitric Oxide Synthase Type III; EC 1.14.13.39/Nos3 protein, rat; EC 1.15.1.1/Superoxide Dismutase; EC 1.6.3.1/NADPH Oxidase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Role of long-term potentiation of sympathetic ganglia (gLTP) in hypertension.
Next Document: Cardiovascular reactivity in patients with essential or renal hypertension under standardized mental...